騰盛博藥-B:2023年度報告
Tengsheng Pharmaceutical-B (02137) granted a total of 5.752,500 share options and 821,500 restricted share units
Tengsheng Pharmaceutical-B (02137) issued an announcement. On March 28, 2024, the company purchased shares in accordance with 2023...
Tengsheng Pharmaceutical-B (02137.HK) will actively seek external cooperation with R&D expenditure of 403 million yuan in 2023
Gelonghui, March 22 | Tengsheng Pharmaceutical-B (02137.HK) announced that for the year ended December 31, 2023, other revenue was RMB 163.7 million, an increase of RMB 55.8 million or 51.7% compared with RMB 107.9 million for the year ended December 31, 2022. This was mainly due to an increase in interest income of RMB 70.8 million due to rising interest rates on US dollar and Hong Kong dollar time deposits. This increase was partially offset by a reduction in revenue recognized by the Chinese government subsidy. For the year ended December 31, 2023, R&D expenditure was for the people
BRII-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Tengsheng Pharmaceutical-B (02137.HK) will hold a board meeting on March 22 to approve the annual results
Gelonghui March 11 | Tengsheng Pharmaceutical-B (02137.HK) issued an announcement. The company will hold a board meeting on March 22, 2024 to review and approve the company's annual results and announcements for the year ended December 31, 2023.
BRII-B: DATE OF BOARD MEETING
After falling nearly 45% in two days and excluding Hong Kong Stock Connect, Tengsheng Pharmaceutical-B (02137) was seriously injured?
As the stock with the worst decline on the list, the reason behind the successive sharp declines of Tengsheng Pharmaceutical-B is not just an appearance on paper.
Here's Why We're Watching Brii Biosciences' (HKG:2137) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success wi
Changes in Hong Kong stocks | Tengsheng Pharmaceutical-B (02137) fell more than 26%, and its stock price hit a new low and was removed from the Hong Kong Stock Connect list
The Zhitong Finance App learned that Tengsheng Pharmaceutical-B (02137) fell by more than 26%, and the intraday low of HK$1.22 hit a new low since listing. As of press release, it decreased by 26.47% to HK$1.25, with a turnover of HK$20.313,900. According to the news, according to the Hong Kong Stock Exchange and the Hong Kong Stock Exchange's adjustment announcements issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange, Tengsheng Pharmaceuticals has been removed from the Hong Kong Stock Connect list, which will take effect today. According to reports, Tengsheng Pharmaceutical announced the discontinuation of production of the COVID-19 neutralizing antibody last year. It is its only commercial product, contributing all of its revenue in 2022. In 2022, the company lost 484 million yuan
Guojin Securities: Chronic Hepatitis B Cure Track has broad potential market space and continues to recommend companies that deploy long-acting interferons and related innovative drugs
The chronic hepatitis B cure track is one of the tracks that the trip continues to be optimistic about and recommended. Clinical cure for chronic hepatitis B has now entered a new stage from early exploration to international recognition to rapid and in-depth development.
Changes in Hong Kong stocks | Tengsheng Pharmaceutical-B (02137) rose more than 9% intraday and recently acquired HBV Pharmaceuticals' intellectual property rights and cancer vaccine development rights in the Asia-Pacific region
Tengsheng Pharmaceutical-B (02137) rose more than 9% in the intraday period. As of press release, it was up 5.14% to HK$1.84, with a turnover of HK$4.926,300.
VBI Vaccines: Received $2.5 M of Consideration Upon Signing of Definitive Documents and Expect to Receive Up to an Additional $30.5M of Consideration, Subject to Achievement of Certain Activities, With a Target Completion Date of June 30 >VBIV
VBI Vaccines: Received $2.5 M of Consideration Upon Signing of Definitive Documents and Expect to Receive Up to an Additional $30.5M of Consideration, Subject to Achievement of Certain Activities, Wit
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement With Brii Biosciences
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement With Brii Biosciences
Brii Biosciences to Buy Rights to Hepatitis B Vaccine From VBI
Brii Biosciences (HKG:2137) will buy all the rights, title, and interest related to the BRII-179 hepatitis B vaccine from VBI Vaccines and subsidiaries Variation Biotechnologies and SciVac for a maxim
[Hong Kong Stock Connect] Tengsheng Pharmaceutical-B (02137) agreed to acquire all intellectual property rights related to BRII-179
Jinwu Financial News | Tengsheng Pharmaceutical-B (02137) announced that on February 13, 2024 (that is, before the trading session on February 14, 2024, Hong Kong time), the Group and VBI contractors agreed to carry out the following transaction: (i) BRII-179 acquisition, according to which VBI and VBICDA agreed to permanently sell worldwide and the company agreed to purchase all rights, ownership and interest in any intellectual property related to BRII-179 (VBI-2601); (ii) technology transfer, according to which VBI will do its best to do business Make reasonable efforts to complete and
Brii Biosciences: Upon Meeting Specific Conditions, the Note Will Increase to $10M, Securing All of VBI's Intellectual Properties for BRII-179, With Associated Payments Also Eliminated
Brii Biosciences: Upon Meeting Specific Conditions, the Note Will Increase to $10M, Securing All of VBI's Intellectual Properties for BRII-179, With Associated Payments Also Eliminated
Brii Biosciences Will Also Take Control of VBI's Rehovot-based Manufacturing Facilities for BRII-179 and PreHevbrio/PreHevbri for $10M Cash on or After June 30
Brii Biosciences Will Also Take Control of VBI's Rehovot-based Manufacturing Facilities for BRII-179 and PreHevbrio/PreHevbri for $10M Cash on or After June 30
Brii Biosciences: Promissory Note Will Eliminate Royalty and Milestone Payments for PreHevbri
Brii Biosciences: Promissory Note Will Eliminate Royalty and Milestone Payments for PreHevbri
Brii Biosciences Will Issue $2.5M Promissory Note to VBI Initially
Brii Biosciences Will Issue $2.5M Promissory Note to VBI Initially
Brii Biosciences Announces Agreement to Acquire VBI Vaccines' IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Comml Supplies
Brii Biosciences Announces Agreement to Acquire VBI Vaccines' IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Comml Supplies
No Data